98%
921
2 minutes
20
Mangrove forest conservation can help reduce global C emissions. Despite this benefit to climate change mitigation and adaptation, mangrove forests are being deforested or degraded at an alarming rate, though restoration efforts may offset these losses. The impacts of deforestation to C stocks are relatively intuitive and result in significant decreases in C stocks. It remains unclear how degradation from selective harvesting of trees affects C stocks or how effective restoration efforts are at restoring C stocks. Furthermore, total ecosystem C (TEC) stocks of pristine mangroves can significantly vary spatially. To address these issues, we conducted an intensive, national assessment of mangrove forests across Cambodia using a grid approach to: 1) examine how land use land cover (i.e., pristine, deforested, degraded, and restored forests) impacts TEC stocks, and 2) how TEC stocks vary spatially across the country. TEC stocks from deforested mangroves were always lower than pristine forests, resulting in an overall loss of 60% C (480 Mg C ha). However, TEC stocks from degraded and 25-year-old restored mangroves forests did not differ from pristine forests. Mean TEC in mangroves was 784.7 ± 30.1 Mg C ha, decreasing from 957.2 ± 32.8 Mg C ha in the northern region to 628.9 ± 33.1 Mg C ha in the central region to 386.2 ± 19.1 Mg C ha in the southern region of Cambodia. Intensive sampling in mangroves across Cambodia verified impacts of deforestation reported elsewhere, revealed the lack of degradation impacts on TEC stocks, and demonstrated the effectiveness of restoration on TEC stocks after only 25 years. Our gridded sampling approach was able to capture spatial variability across Cambodia and provide a more realistic TEC stock information that can be used for national reporting or participation in C markets.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.scitotenv.2019.135416 | DOI Listing |
Nat Biotechnol
July 2025
Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Characterizing shared patterns of RNA expression between genes across conditions has led to the discovery of regulatory networks and biological functions. However, it is unclear if such coordination extends to translation. In this study, we uniformly analyze 3,819 ribosome profiling datasets from 117 human and 94 mouse tissues and cell lines.
View Article and Find Full Text PDFAllergy
August 2025
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Background: Alopecia areata (AA) is an autoimmune disease characterized by hair loss. This study examined changes in molecular signatures in lesional scalp of patients with AA subtypes (patchy-type AA [AAP] or alopecia totalis/alopecia universalis [AT/AU]) in response to treatment with JAK3/TEC family kinase inhibitor ritlecitinib and evaluated correlations between potential biomarker levels/changes and scalp hair regrowth.
Methods: This was a post hoc analysis of a biopsy substudy from a phase 2a trial of ritlecitinib in patients with AA and ≥ 50% scalp hair loss.
Br J Clin Pharmacol
August 2025
Pfizer Inc, La Jolla, CA, USA.
Aims: To assess the effect of a potent cytochrome P450 (CYP) 3A inhibitor and CYP inducer on the pharmacokinetics of ritlecitinib, a JAK3/TEC family kinase inhibitor, and assess the effect of ritlecitinib on the pharmacokinetics of CYP substrates (midazolam, efavirenz, tolbutamide, caffeine and oral contraceptives [ethinyl oestradiol and levonorgestrel]) in healthy adults.
Methods: Seven clinical drug-drug interaction studies were analysed. Pharmacokinetic parameters for drugs as measured in blood plasma were used to estimate the drug interaction potential with ritlecitinib as a perpetrator or victim.
Cancers (Basel)
April 2025
Illinois CancerCare, Peoria, IL 61615, USA.
: Teclistamab (TEC) is the first B-cell maturation antigen-directed bispecific antibody approved in 2022 by the European Medicines Agency and Food and Drug Administration for triple-class exposed relapsed/refractory multiple myeloma (RRMM). : As TEC is increasingly used in real-world (RW) settings, this study seeks to gather existing RW evidence on effectiveness, safety, healthcare resource utilization, and clinical practices associated with TEC. : A systematic literature review was performed to identify RW observational studies of TEC-treated adults with RRMM from 2023 to June 2024.
View Article and Find Full Text PDFBioorg Med Chem Lett
August 2025
Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland.
In recent years, lysophospholipase autotaxin (ATX) has emerged as an attractive target for treating a variety of human diseases, including inflammation, neurodegeneration, angiogenesis, cancer, ocular and fibrotic diseases, among others. Starting with the quinazolinone hit structure 1, which emerged from a DNA-encoded library screen, the potent, non-Zn binding ATX inhibitor 31 with good overall physicochemical properties has been developed. This compound demonstrated a sustained reduction of lysophosphatidic acid (LPA) in an in vivo rat experiment, qualifying it as a proof-of-concept compound for further mechanistic studies.
View Article and Find Full Text PDF